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Gender Differences in Clinical
Manifestations of Brugada Syndrome
Begoña Benito, MD,* Andrea Sarkozy, MD,† Lluis Mont, MD, PHD,* Stephan Henkens, RN,†
Antonio Berruezo, MD,* David Tamborero, BENG,* Dabit Arzamendi, MD,* Paola Berne, MD,*
Ramon Brugada, MD, PHD,‡ Pedro Brugada, MD, PHD,† Josep Brugada, MD, PHD*
Barcelona, Spain; Brussels, Belgium; and Montreal, Quebec, Canada
Objectives We sought to assess differences in phenotype and prognosis between men and women in a large population of
patients with Brugada syndrome.
Background A male predominance has been reported in the Brugada syndrome. No specific data are available, however, con-
cerning gender differences in the clinical manifestations and their role in prognosis.
Methods Patients with Brugada syndrome were prospectively included in the study. Data on baseline characteristics, elec-
trocardiogram parameters before and after pharmacological test, and events in follow-up were recorded for all
patients.
Results Among 384 patients, 272 (70.8%) were men and 112 (29.2%) women. At inclusion, men had experienced syn-
cope more frequently (18%) or aborted sudden cardiac death (6%) than women (14% and 1%, respectively, p 
0.04). Men also had greater rates of spontaneous type-1 electrocardiogram, greater ST-segment elevation, and
greater inducibility of ventricular fibrillation (p  0.001 for all). Conversely, conduction parameters and corrected
QT intervals significantly increased more in women in response to sodium blockers (p  0.03 and p  0.001,
respectively). During a mean follow-up of 58  48 months, sudden cardiac death or documented ventricular fi-
brillation occurred in 31 men (11.6%) and 3 women (2.8%; p  0.003). The presence of previous symptoms was
the most important predictor for cardiac events in men, whereas a longer PR interval was identified among
those women with a greater risk in this series.
Conclusions Men with Brugada syndrome present with a greater risk clinical profile than women and have a worse prognosis.
Although classical risk factors identify male patients with worse outcome, conduction disturbances could be a
marker of risk in the female population. (J Am Coll Cardiol 2008;52:1567–73) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.052B
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mrugada syndrome was first described in 1992 as a clinical
yndrome presenting with a characteristic electrocardiogram
ECG) morphology (incomplete right bundle branch block
ssociated with ST-segment elevation) and susceptibility to
entricular arrhythmias and sudden cardiac death (SCD)
1). After few initial clinical reports, the first mutations
esponsible for the syndrome were described in 1998 in the
CN5A gene, which encodes the cardiac sodium channel
2). Functional studies of these and other subsequent
utations described on the same gene showed that the
rom the *Cardiology Department, The Thorax Institute, Hospital Clı´nic, University
f Barcelona, Barcelona, Spain; †Heart Rhythm Management Centre, Cardiovascular
nstitute, UZ Brussel, VUB Brussels, Belgium; and the ‡Cardiovascular Genetics
enter, Montreal Heart Institute, University of Montreal, Montreal, Quebec,
anada. Supported by Plan Nacional de Investigacio´n Cientı´fica, Desarrollo e
nnovacio´n Teconolo´gica (IDI), Instituto de Salud Carlos III/FIS (ref. CM06/
0189) (Spain) and Sociedad Española de Cardiologı´a: Beca para formacio´n end
entros extranjeros (Spain).
Manuscript received June 23, 2008, accepted July 30, 2008.rugada phenotype appeared as a consequence of a loss of
unction in the sodium channel (2–4). Recently, a new
utation in the glycerol-3 phosphate dehydrogenase-1 like
GPD1-L) gene that decreases the trafficking of sodium
urrents also has been connected to the syndrome (5). Both
CN5A and GPD1-L genes are on chromosome 3 and,
hus, are not presumably linked to gender (2,5). Indeed,
rugada syndrome presents an autosomal-dominant mode
f transmission with low penetrance (6).
Despite the syndrome not being linked to gender, the
rugada phenotype has been reported to be up to 8 to 10
imes more prevalent in men than in women (6,7). In fact,
1% to 77% of the patients included in the main clinical
tudies of Brugada syndrome are men (8–11). The same
linical studies have shown that compelling clinical events
uch as SCD or ventricular fibrillation (VF) tend to occur
ore frequently in men than in women (8–12). These datao nothing other than to confirm what was already known
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Gender Differences in Brugada Syndrome November 4, 2008:1567–73in some Southeast Asian villages
regarding sudden unexplained
death syndrome (i.e., SUDS),
considered now to be the same
disorder as Brugada syndrome
(13), where men used to dress in
female bedclothes given that
SUDS was thought to be a fe-
male spirit searching for young
men at the time of sleep.
Several hypotheses have been
raised to explain the gender dif-
ferences in Brugada syndrome,
supporting either constitutional
differences in ionic currents be-
tween genders (14), or a role of
sex hormones since the time of
puberty and throughout life
(15,16). However, despite the
general agreement of a male pre-
dominance in the Brugada syn-
drome phenotype, specific data
on how gender influences the
linical manifestations and prognosis of patients are lacking.
oreover, no information regarding differences in risk
arkers according to gender has been available thus far. In
his study, we sought to establish, in a large population of
atients with Brugada syndrome, the clinical phenotype of
oth men and women and to compare their clinical evolution.
ethods
tudy population. Patients for this study were recruited
ither in Hospital Clinic of Barcelona or in UZ Brussel
ospital and followed prospectively. Although both study
ospitals are international referral centers for Brugada
yndrome, only those patients directly evaluated and fol-
owed by 1 of the 2 centers were included in the study to
inimize high-risk selected population bias (inclusion pe-
iod 1992 to 2007). Patients from other centers who had
een referred for evaluation and/or a second opinion but had
ot subsequently been followed by the 2 centers and patients
ho were referred for the international database were
xcluded. This process guaranteed a more representative
opulation and that all patients underwent the same study
rotocol.
A spontaneous or induced (after sodium-blocker admin-
stration) coved-type ECG pattern (type-1 ECG) was
equired in all patients. Type-1 ECG was defined as
escendent ST-segment elevation 2 mm in right precor-
ial leads followed by a negative T-wave, as stated in the
onsensus (17). Sodium-blocker administration was per-
ormed with ajmaline (1 mg/kg of body weight), flecainide
2 mg/kg of body weight), or procainamide (10 mg/kg of
ody weight) according to drug availability in the 2 centers.
Abbreviations
and Acronyms
CI  confidence interval
ECG  electrocardiogram
EPS  electrophysiological
study
GPD1-L  glycerol-3
phosphate dehydrogenase-1
like
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
Ito  potassium current
QTc  corrected QT
interval
SCD  sudden cardiac
death
SUDS  sudden
unexplained death
syndrome
VF  ventricular fibrillationn echocardiography, chest X-ray, and other cardiac explo- iations when needed were performed to definitely rule out
tructural heart disease.
linical data. At baseline, clinical data regarding age, family
istory, symptoms at presentation, and ECG were collected.
aseline ECG was defined as type 1, type 2, or type 3/normal
atterns. Baseline PR interval, QRS duration, and QT interval
orrected for the Bazzet’s formula (QTc) were measured in
illiseconds. Analysis of ST-segment elevation was performed
n lead V2 at 40 ms from the J point. The same measurements
PR interval, QRS duration, QT interval, and ST-segment
levation) were obtained after pharmacological test, provided it
as performed.
All patients were recommended to undergo electrophys-
ological study (EPS). The protocol was identical for all. At
aseline and in the absence of any drugs, conduction
ntervals were obtained. Ventricular stimulation was per-
ormed at a single site (right ventricular apex), with induc-
ion of 1, 2, or 3 ventricular premature beats down to a
inimum of 200 ms, over basal rhythm, and over pacing
ycle lengths of 600, 500, and 430 ms.
Single- or dual-chamber implantable cardioverter-
efibrillators (ICDs) were indicated in accordance with the
urrent recommendations (17), that is, in high-risk patients
resenting with SCD (class I), in patients presenting with
yncope with spontaneous (class I) or induced (class IIa)
ype-1 ECG, or in asymptomatic patients with family
istory of SCD and inducibility of VF at the EPS, either
ith spontaneous type-1 ECG (class IIa) or with induced
ype-1 ECG (class IIb).
All patients were directly followed by 1 of the 2 participating
enters. Cardiac events were defined as SCD or documented
F, and recorded for all patients during follow-up. Syncope
as not included in the definition because we sought to record
nly confirmed life-threatening events.
tatistical analysis. Results are reported as mean  SD or
requency as appropriate. Comparisons between groups
ere performed with the Student t test or chi-square
nalysis. Differences of ECG parameters before and after
he administration of sodium-blockers were tested with the
se of a paired Student t test. The relationship between
aseline data and the time to event during follow-up was
valuated with survival analysis methodology (i.e., Cox
egression models). Variables were included in the multiva-
iable analysis with the use of a forward stepwise procedure
ith a criteria of p  0.05 for inclusion and p  0.10 for
emoval from the model. Cumulative event rates were
stimated by Kaplan-Meier estimation, and plots were
ompared by the log-rank test. A p value of 0.05 was
onsidered statistically significant. Statistical analyses were
erformed using SPSS 14.1 software package (SPSS Inc.,
hicago, Illinois).
esults
aseline clinical data. A series of 384 patients were
ncluded in the study; 272 were men (70.8%) and 112 were
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November 4, 2008:1567–73 Gender Differences in Brugada Syndromeomen (29.2%). This male predominance is in accordance
o previous studies (8–11) and confirms that Brugada
yndrome more frequently is diagnosed among men than
omen. The general characteristics of the study population
re summarized in Table 1. Most patients were asymptom-
tic at the time of diagnosis, although men presented more
requently with symptoms as compared with women. This
ifference was more remarkable regarding SCD, which was
resent in 17 of 272 men (6%) and only in 1 of 112 women
1%, p  0.01). Interestingly, of the 18 patients who first
ame with SCD, 9 had had previous syncope. Previous atrial
brillation did not significantly differ between men and
omen.
Baseline ECG showed typical features of Brugada syn-
rome more frequently in men, given that type-1 ECG, the
nly definite diagnostic ECG pattern of Brugada syndrome,
as present in 128 men (47%), whereas it was present in
nly 26 women (23%, p  0.001). Likewise, ST-segment
levation in basal ECG among those patients who sponta-
eously showed a type-1 ECG was significantly greater in
en as compared with women (3.5  1.8 mm vs. 2.5  0.7
m, p  0.001).
The EPS was performed in 350 patients (91.1%). Two
atients did not undergo EPS because 1 presented with
CD as the first symptom and died during the same
ospital admission and other developed severe brain damage
fter cardiac arrest. In 1 patient, VF requiring cardiopulmo-
eneral Characteristics of the Study Population
Table 1 General Characteristics of the Study Population
Men
(n  272)
Women
(n  112) p Value
Age at diagnosis, yrs 45 14 48 18 0.09
Family history of SCD, n (%) 82 (31) 50 (45) 0.007
Symptoms at diagnosis, n (%) 0.04
None 206 (76) 95 (85)
Syncope 49 (18) 16 (14)
Aborted SCD 17 (6) 1 (1)
Previous AF, n (%) 26 (10) 14 (12) 0.2
Baseline ECG
Normal or type-3, n (%) 68 (25) 69 (62) 0.001
Type-2, n (%) 76 (28) 17 (15)
Type-1, n (%) 128 (47) 26 (23)
PR interval, ms 176 31 176 35 1
QRS duration, ms 107 17 98 19 0.001
QTc interval, ms 422 47 422 49 1
ST-segment elevation, mm* 3.5 1.8 2.5 0.7 0.001
Pharmacological test, n  312 (%) 210/272 (77) 102/112 (91) 0.001
Drug (ajmaline/flecainide/
procainamide)
133/65/12 73/28/1 0.09
EPS, n  350 (%) 259/272 (95) 91/112 (81) 0.001
Inducible, n (%) 84 (32) 11 (12) 0.001
Noninducible, n (%) 175 (68) 80 (88)
HV interval, ms 48 10 47 8 0.4
ICD, n (%) 103 (38) 24 (22) 0.002
Follow-up, months 57 52 60 40 0.48
Only for patients with spontaneous type-1 electrocardiogram (ECG) (n  154).(
AF  atrial fibrillation; EPS  electrophysiological study; ICD  implantable cardioverter-
efibrillator; QTc  corrected QT interval; SCD  sudden cardiac death.ary resuscitation occurred during the pharmacological test
ith sodium blockers, and EPS was not performed. Addi-
ionally, the EPS was not performed in 11 asymptomatic
hildren with spontaneous normal ECG and age16 years.
nother 20 patients refused to undergo the procedure,
ainly given their low risk profile (asymptomatic with
ormal ECG at baseline). Despite identical protocols of
entricular stimulation for both men and women, the rate of
nducibility of ventricular arrhythmias was significantly
igher in males (32% vs. 12%, p  0.001). No differences
ere observed in basal conduction intervals during EPS
etween the 2 groups.
The effects of the administration of a sodium-blocker on
he ECG parameters are depicted in Table 2. Note that only
atients who underwent the pharmacological test are pre-
ented (n  312). In the presence of pharmacological
odium-blockade, the PR interval, QRS duration, QTc
nterval, and ST-segment elevation significantly increased in
oth men and women. This increase was greater in women
egarding conduction parameters (PR interval, a trend in
RS duration) and QTc interval, whereas the increment of
T-segment elevation did not significantly differ between
en and women.
Overall, men displayed a greater risk-profile at baseline
han women. Indeed, male gender increased by 7.4 the risk
f presenting with SCD at the time of diagnosis (95%
onfidence interval [CI]: 1.0 to 55.5), by 2.9 the risk of
isplaying spontaneous type-1 ECG (95% CI: 1.8 to 4.8),
r by 3.5 the rate of inducibility of ventricular arrhythmias
t the EPS (95% CI: 1.8 to 6.9), with regard to women.
iven their greater risk profile, men were more likely to
eceive an ICD than women (38% vs. 22%, p  0.002).
linical outcomes. In the entire study population, cardiac
vents defined as SCD or documented VF occurred in 34 of
84 (8.9%) patients during a mean follow-up of 58  48
onths. Specifically, 27 appropriate ICD discharges, 6
CD (nonresuscitated), and 1 (resuscitated) documented
F were recorded. The rate of events was significantly
reater among those patients who had presented with
yncope (10 of 65 events, 15.4%) or aborted SCD (11 events
f 18, 61.1%) at the time of diagnosis than among previ-
usly asymptomatic patients (13 events of 301, 4.3%, p 
.001).
Despite similar follow-up periods in both genders (Table
), cardiac events appeared in 31 men (11.6%) but only in 3
omen (2.8%, p  0.003). Kaplan-Meier estimate of
ardiac event-free survival according to gender is repre-
ented in Figure 1. With the use of univariable analysis, we
ound that gender was significantly related to cardiac events
hazard ratio [HR]: 4.45, 95% CI: 1.36 to 14.58, p 
.014), along with other variables such as symptoms at the
ime of diagnosis, spontaneous type-1 ECG, inducibility of
F during EPS, or atrial fibrillation (Table 3). However,
he use of multivariable analysis did not confirm gender as
n independent predictor of cardiac events during follow-up
Table 3).
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Gender Differences in Brugada Syndrome November 4, 2008:1567–73Because the clinical presentation was notoriously different
n men and women, we analyzed separately the 2 popula-
ions to assess the characteristics of patients at risk for both
enders. The results are summarized in Table 4. Male
atients who developed cardiac events were more likely to
e previously symptomatic and had more frequently spon-
aneous type-1 ECG, inducibility of VF, and history of
revious AF (p  0.05) than male patients who did not
evelop cardiac events. The presence of symptoms at the
ime of diagnosis defined those patients at greater risk for
vents, which occurred in 18.4% of patients with previous
yncope, in 64.7% of those with previous aborted SCD and
nly in 5.5% of previously asymptomatic patients (p 
.001). In fact, symptoms were the only independent
redictor for a worse prognosis in the multivariable analysis
HR: 3.4, 95% CI: 1.3 to 8.1 for syncope, p  0.01; and
R: 13.8, 95% CI: 5.5 to 34.6 for SCD, p  0.001) for the
ale population.
Conversely, in the presence of an extremely low rate of
ardiac events in women (2.8%), none of the classically
CG Parameters in Those Patients Who Underwent the Pharmacoloalues Before and After Adminis ration of th Sodium-Blocker
Table 2 ECG Parameters in Those Patients Who Underwent theValues Before and After Administration of the Sodium-B
Men
Baseline After Sodium-Blocker p
PR interval, ms 173 31 204 34 
QRS duration, ms 105 16 130 24 
QTc interval, ms 417 45 458 51 
ST-segment elevation, mm 2.3 1.6 4.2 1.9 
p value in the paired t test for intragroup comparisons of ECG parameters before and after th
dministration of sodium-blockers. †p value in the t test for intergroup comparisons (men vs. wom
Tc intervals was significantly greater than in men, and a trend also was observed for the QRS du
Abbreviations as in Table 1.
Figure 1 Kaplan-Meier Estimate of Cardiac
Event-Free Survival According to Gender
Kaplan-Meier analysis of cardiac events in follow-up, defined as sudden cardiac
death (SCD) or documented ventricular fibrillation (VF), in male and female patients.oeported risk markers (8–12) showed enough power to
dentify those female patients with worse outcome. For
xample, 2 of the 3 events appeared in previously asymp-
omatic women (Table 4). Interestingly, conduction param-
ters such as the PR interval or the HV interval were
ignificantly longer in female patients who developed car-
iac events (Table 4). The former, with the limitations as a
esult of the scarce number of events, was actually the only
ndependent predictor for cardiac events in the female
opulation (multivariable analysis: HR 1.03 per each ms of
ncrease in the PR interval, 95% CI: 1.01 to 1.05, p 0.03).
iscussion
n this study, we aimed to analyze the differences in clinical
anifestations of Brugada syndrome according to gender.
n a series of 384 patients with Brugada syndrome, men
ere predominant (70.8%) and displayed a higher risk
rofile as compared with women, as well as a greater event
ate in follow-up. In the male population, cardiac events
ere more frequent among patients with previous symp-
oms, spontaneous type-1 ECG, or inducibility of VF in the
PS. Women showed more conduction disturbances and
onger QTc interval in response to sodium blockers. In the
resence of a very low event rate, conduction parameters
ppeared to be related to a worse outcome in the female
opulation.
To date, several hypotheses have been raised to explain
he gender differences in Brugada syndrome. The role of
pecific mutations seems to be of minor influence because,
n the one hand, patients with and without identified
CN5A mutations display a similar male predominance
7,18,19) and, on the other hand, the same single mutation
as been described for both a family with male predomi-
ance and another one with female phenotypic predomi-
ance (13,20). In addition, no evidence exists of a gender
nfluence of the new reported mutation on the GPD1-L
ene (5). Two other hypotheses seem more likely to play a
ole in the gender distinction of Brugada phenotype, per-
aps interacting with each other: the gender-related intrin-
ic differences in ionic currents and the hormonal influence.
Di Diego et al. (14) elegantly demonstrated that transient
l Test:
rmacological Test:
er
Women
p Value†* Baseline After Sodium-Blocker p Value*
173 35 211 43 0.001 0.03
98 16 128 27 0.001 0.06
418 47 486 47 0.001 0.001
1.6 1.0 3.4 1.5 0.001 0.8
acological test. All ECG parameters significantly increased in both men and women after the
the increment in ECG parameters after pharmacological test. In women, the increment of PR and
ST-segment elevation increased equally in men and in women.gica
Pha
lock
Value
0.001
0.001
0.001
0.001
e pharm
en) ofutward potassium current (Ito) density quantified by
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November 4, 2008:1567–73 Gender Differences in Brugada Syndromehole-cell patch-clamp techniques was significantly greater
n male than female right ventricle epicardia of arterially
erfused canine heart preparations, thus explaining the
eeper notch in phase 1 of the action potential in men as
ompared with women. The electrophysiological implica-
ions of these findings were assessed in the same model by
he administration of a sodium-calcium blocker and subse-
uently confirmed by other groups (21). Two effects were
oted: the use of terfenadine induced, first, transmural
ispersion of repolarization, thus leading to the character-
stic ST-segment elevation of Brugada syndrome, and,
econd, epicardial dispersion of repolarization that might
acilitate all-or-none repolarization, thus favoring phase-2
e-entry and VF (14). Both phenomena were mainly ob-
erved in male samples because of their deeper Phase 1
agnitude at baseline.
In our study, we provide clinical confirmation of these
xperimental findings. In accordance with the work of Di
iego et al. (14), our male population displayed more
athological ECGs at baseline as compared with our female
opulation. Type-1 ECG at diagnosis was significantly
ore frequent in men than in women (47% vs. 23%, p 
.001) and, among patients displaying spontaneous type-1
CG, ST-segment elevation also was significantly greater
n men (3.5  1.8 mm vs. 2.5  0.7 mm, p  0.001). On
he other hand, men also had a significantly greater rate of
ariables Related to the Occurrence of Cardiac Events During Follo
Table 3 Variables Related to the Occurrence of Cardiac Events
Univariable Analysis
HR 95% CI
Gender 4.45 1.36–14.58
Previous AF 2.63 1.24–5.58
Symptoms at diagnosis
Syncope 3.43 1.5–7.83
Aborted SCD 11.59 5.01–26.79
Spontaneous type-1 ECG 2.7 1.3–5.58
Inducibility of VF (EPS) 5.33 2.34–12.15
ardiac events are defined as SCD or documented VF.
CI  confidence interval; ECG  electrocardiogram; HR  hazard ratio; VF  ventricular fibrilla
haracteristics of the Patients With Cardiac Events in Male and Fe
Table 4 Characteristics of the Patients With Cardiac Events in
Male Population
No Events (n  241) Events (n 
Symptoms at diagnosis, n (%) 46 (19) 20 (64)
Previous AF, n (%) 18 (7) 8 (26)
Spontaneous type-1 ECG, n (%)* 105 (43) 21 (67)
PR interval, ms* 175 30 178 40
QRS duration, ms* 107 17 110 18
QTc interval, ms* 421 48 432 42
ST-segment elevation*† 3.6 2 3 1
Inducibility of VF, n (%) 64/232 (28) 20/27 (74
HV interval 48 10 46 7ardiac events are defined as SCD or documented VF. *Indicates parameters in the basal ECG. †Indicate
Abbreviations as in Tables 1 and 3.F than women, both before the diagnosis (6% vs. 1%, p 
.01) and during follow-up (11.6% vs. 2.8%, p  0.003),
lthough in our series, male gender per se was not an
ndependent predictor of cardiac events. Our findings are
lso in the same line than the ones from other clinical works
n which men are reported to display more ST-segment
levation (22) and greater events in follow-up (12).
This study also demonstrates that, despite similar baseline
CG parameters, women experience a greater increase of
R interval, QRS duration, and QTc interval after exposure
o sodium-blockers than men (Table 2). Cardiac conduction
isturbances have been reported in sodium loss-of-function
onditions and specifically combined with Brugada syn-
rome within the same family (23). Interestingly, a gender-
elated difference could be observed in this family, in which
en predominantly presented with Brugada phenotype and
omen with isolated conduction disturbances (23). Subse-
uent experimental studies demonstrated that, in the pres-
nce of sodium blockade, the smaller Ito in women predis-
oses them to progressive conduction disorders, whereas the
reater Ito in men explains their greater ST-segment
levation (24). Accordingly, in our clinical study, the expo-
ure to a sodium-blocker produced a greater increase in
onduction parameters in females as compared with men.
owever, the differences of increase in ST-segment eleva-
ion were not statistically significant between both genders.
in the Entire Population (Cox Regression Model)
ng Follow-Up in the Entire Population (Cox Regression Model)
Overall Population
Multivariable Analysis
p Value HR 95% CI p Value
0.014 2.82 0.64–12.41 NS
0.012 2.16 0.93–5.03 0.07
0.003 1.86 0.7–4.97 NS
0.001 8.45 3.17–22.55 0.001
0.008 1.4 0.59–3.33 NS
0.001 2.93 1.14–7.55 0.02
er abbreviations as in Table 1.
Populations
and Female Populations
Female Population
p Value No Events (n  109) Events (n  3) p Value
0.001 16 (15) 1 (33) NS
0.005 12 (11) 2 (67) 0.04
0.01 23 (21) 2 (67) NS
NS 173 32 240 62 0.001
NS 97 16 130 62 NS
NS 420 49 486 47 0.06
NS 2.4 1 3.2 1 NS
0.001 10/89 (11) 1/2 (50) NS
NS 46 8 60 11 0.02w-Up
Durimale
Male
31)
)s parameters exclusively in patients with spontaneous type-1 ECG.
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Gender Differences in Brugada Syndrome November 4, 2008:1567–73n the other hand, experimental works have shown that
emale rabbit ventricular myocytes have significantly lower
Kr and IKI current densities (25) and greater epicardial
CaL (26) than male rabbits, which could explain the
reater susceptibility of women to develop longer QT
ntervals and early afterdepolarizations or torsades de
ointes (21,27). Thus, the differences in IK currents be-
ween genders are expected to be the basis for the greater
rolongation of the QTc interval observed in our female
opulation after exposure to sodium blockers, because all
he 3 drugs used in this study (ajmaline, flecainide, and
rocainamide) have known IKr blocking effect.
Hormonal influence might also play a role in the pheno-
ypic manifestations of Brugada syndrome (28), which
ould explain the regression of the typical ECG features
eported in castrated men (15) and the greater levels of
estosterone present in Brugada male patients as compared
ith control patients (16). Some experimental data point
ut that hormones could modify the ionic membrane
urrents, with estrogens having been reported to inhibit Ito
xpression and trafficking (29) and testosterone to increase
Ks slow potassium currents (30). Consequently, with this
ypothesis, the few available data existing thus far of
rugada syndrome in children have not shown a difference
n phenotypic presentation between boys and girls (31). The
opulation in this study mainly was of adult patients (95.6%
ere 18 years of age). Thus, conclusions about a gender
istinction in Brugada syndrome during childhood, and
pecifically before the hormonal influence of adolescence,
annot be taken from these data.
Identifying the markers of risk of SCD in patients with
rugada syndrome has been a matter of great interest in the
ast years (8–12). In contrast to the previous series of our
roup, embracing patients from the international database
8,10), this study included only those patients directly
tudied and followed by the 2 participating centers, because
e sought to minimize a high-risk selected population bias
nd to ensure an identical study protocol for all patients.
nterestingly, in this study we assessed the characteristics of
atients at risk separately in men and women. In accordance
o the results reported for previous mixed populations
8–12), high-risk male patients had more previous symp-
oms, more spontaneous type-1 ECG, and more inducibil-
ty of VF at the EPS. On the other hand, the event rate in
he female population appeared considerably lower than that
f the male population. Despite the inclusion in our study of
he largest population of female patients described thus far,
n the presence of such low rate of cardiac events, only the
onduction parameters consistently differ between women
ho experienced SCD or VF and those who did not.
pecifically, the PR interval was the best marker of risk for
he female population in our series, although this result
hould be interpreted cautiously given the small number of
vents. One plausible interpretation is that longer PR
ntervals reflect greater sodium channel dysfunction and,hus, a deeper defect leading to greater susceptibility for
entricular arrhythmias.
tudy limitations. Changes on ECG parameters after
xposure to sodium blockers were evaluated for the overall
opulation, even though not all patients received the same
rug. The possible bias due to these differences was atten-
ated by the fact that the percentage of the drugs adminis-
ered in men and women did not significantly differ.
onclusions
n this prospective 2-center study including 384 patients
ith Brugada syndrome, men (70.8%) were the predomi-
ant gender represented and displayed a greater risk profile
t baseline as compared with women, with more patholog-
cal ECG features, a greater rate of symptoms, and a greater
nducibility of ventricular arrhythmias at the EPS. Women
howed greater conduction intervals and a corrected QT
nterval in response to sodium-blockers. Cardiac events in
he longest follow-up reported thus far were significantly
reater in men, although gender was not an independent
redictor of a worse outcome. Classic risk factors identified
ale patients with worse outcome, being the presence of
revious symptoms the most important predictor of events
n the male population. Conversely, conduction distur-
ances appeared to be a marker of risk in this female
opulation. This study confirms that men have a worse
rognosis than women with Brugada syndrome.
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